About This Show
For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals.
DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship.Read more »
Most Recent Episode
May 2018: Does pulmonary rehabilitation need more PR?
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the evidence for pulmonary rehabilitation for COPD and highlight the need for more publicity for its benefits. Read the editorial here: http://dtb.bmj.com/content/56/5/49.
The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).Read more »